• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Paysign, Inc. Awarded 132 Plasma Centers for Immediate Transition

    6/5/25 7:00:00 AM ET
    $PAYS
    Business Services
    Consumer Discretionary
    Get the next $PAYS alert in real time by email

    The Additions Significantly Increase the Company's U.S. Plasma Market Share

    Paysign, Inc. (NASDAQ: PAYS), a leading provider of patient affordability solutions, financial technology products, and integrated payment processing services, today announced that it has been awarded 132 established plasma donation centers through an expansion of its long-standing relationship with a major plasma collection company. Transition of the centers from the incumbent provider is underway, with 123 centers expected to be live by the end of the second quarter of 2025 and the remaining nine slated for transition during the third quarter of 2025.

    "The addition of these centers underscores the strengths of the Paysign donor compensation platform and our ongoing investment in the plasma industry, as well as the hard work and dedication of the entire Paysign team," said Mark Newcomer, President and CEO of Paysign. "This expansion once again reflects the confidence our clients, partners and customers have in our ability to deliver reliable, scalable and innovative solutions. It also reaffirms our position as a trusted partner to the plasma industry, where maximizing the donor experience is paramount."

    With the addition of these centers, Paysign will be providing donor compensation programs to more than 615 plasma centers across 18 plasma collection companies, increasing the number of centers the company supports by 27% and bringing its U.S. market share to approximately 50%. The additional centers will drive immediate revenue growth for Paysign's plasma business.

    Following onboarding, the centers are expected to reach approximately 80% of Paysign's average revenue per center within the first few weeks and reach full revenue contribution by the end of the first quarter of 2026. Notably, the company does not anticipate a corresponding increase in Selling, General and Administrative (SG&A) expenses related to these new centers, highlighting the operating leverage inherent in its business model.

    Forward-Looking Statements

    Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934 and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the companies, are forward-looking statements that involve risks and uncertainties. There is no assurance that such statements will prove to be accurate, and actual results and future events could differ materially. Paysign undertakes no obligation to publicly update or revise any statements in this release, whether as a result of new information, future events or otherwise.

    About Paysign

    Paysign, Inc. is a leading provider of prepaid card programs, comprehensive patient affordability offerings, financial technology products and integrated payment processing designed for businesses, consumers and government institutions. Incorporated in 1995 and headquartered in southern Nevada, the company creates customized, innovative payment solutions for clients across all industries, including pharmaceutical, healthcare, hospitality, and retail. Built on the foundation of a reliable payments platform, Paysign's end-to-end technologies securely enable digital payout solutions and facilitate the distribution of funds for donor compensation, copay assistance, customer incentives, employee rewards, travel expenses, per diem, reimbursements, rebates, and countless other exchanges of value. Paysign's solutions lower costs, streamline operations and improve customer, employee and partner loyalty. To learn more, visit paysign.com.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250605055513/en/

    Investor Relations

    [email protected]

    888.522.4853

    paysign.com/investors

    Media Relations

    Alicia Ches

    888.522.4850

    [email protected]

    Get the next $PAYS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PAYS

    DatePrice TargetRatingAnalyst
    12/20/2024$6.00Buy
    Lake Street
    3/30/2022$4.00Mkt Perform
    Barrington Research
    3/24/2022Buy → Neutral
    Ladenburg Thalmann
    8/20/2021$3.50Neutral → Buy
    DA Davidson
    8/19/2021Neutral → Buy
    DA Davidson
    8/12/2021$3.50 → $3.75Neutral → Buy
    Ladenburg Thalmann
    More analyst ratings

    $PAYS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Paysign, Inc. Awarded 132 Plasma Centers for Immediate Transition

      The Additions Significantly Increase the Company's U.S. Plasma Market Share Paysign, Inc. (NASDAQ: PAYS), a leading provider of patient affordability solutions, financial technology products, and integrated payment processing services, today announced that it has been awarded 132 established plasma donation centers through an expansion of its long-standing relationship with a major plasma collection company. Transition of the centers from the incumbent provider is underway, with 123 centers expected to be live by the end of the second quarter of 2025 and the remaining nine slated for transition during the third quarter of 2025. "The addition of these centers underscores the strengths of

      6/5/25 7:00:00 AM ET
      $PAYS
      Business Services
      Consumer Discretionary
    • Paysign, Inc. to Present at the MicroCap Rodeo Spring Conference

      Paysign, Inc. (NASDAQ: PAYS), a leading provider of prepaid card programs, comprehensive patient affordability offerings, digital banking services and integrated payment processing, today announced its CFO, Jeff Baker, will be attending and presenting at the MicroCap Rodeo Spring Conference in New York City on Wednesday, June 4, 2025. The presentation will be at 3:00 p.m. Eastern time on Wednesday, June 4, and will be webcast live. Interested parties can register to watch the virtual presentation. Management will also be available for one-on-one meetings with approved investors. Investors interested in attending may visit the event website for more information and to pre-register. Abo

      5/29/25 4:30:00 PM ET
      $PAYS
      Business Services
      Consumer Discretionary
    • Paysign, Inc. Reports First Quarter 2025 Financial Results

      First quarter 2025 total revenues of $18.60 million, up 41.0% from first quarter 2024 First quarter 2025 net income of $2.59 million, or diluted earnings per share of $0.05, versus net income of $309 thousand, or diluted earnings per share of $0.01, for first quarter 2024 First quarter 2025 Adjusted EBITDA of $4.96 million, up 193.3% from $1.69 million a year ago, while diluted Adjusted EBITDA per share was $0.09 versus $0.03 for first quarter 20241 Total plasma center count increased by four net centers during first quarter 2025, exiting the quarter with 484 centers; revenue per plasma center decreased to $6,517 compared to $7,414 for the same period last year; year-over-year plasma

      5/8/25 4:05:00 PM ET
      $PAYS
      Business Services
      Consumer Discretionary

    $PAYS
    SEC Filings

    See more
    • Paysign Inc. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits

      8-K - Paysign, Inc. (0001496443) (Filer)

      6/5/25 9:00:50 PM ET
      $PAYS
      Business Services
      Consumer Discretionary
    • Paysign Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Paysign, Inc. (0001496443) (Filer)

      5/12/25 9:00:07 PM ET
      $PAYS
      Business Services
      Consumer Discretionary
    • SEC Form 10-Q filed by Paysign Inc.

      10-Q - Paysign, Inc. (0001496443) (Filer)

      5/9/25 8:28:17 AM ET
      $PAYS
      Business Services
      Consumer Discretionary

    $PAYS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Henry Daniel R bought $67,716 worth of shares (19,800 units at $3.42), increasing direct ownership by 25% to 99,800 units (SEC Form 4)

      4 - Paysign, Inc. (0001496443) (Issuer)

      5/28/25 8:07:31 PM ET
      $PAYS
      Business Services
      Consumer Discretionary
    • Mina Bruce A bought $5,801 worth of shares (1,206 units at $4.81), increasing direct ownership by 0.56% to 218,500 units (SEC Form 4)

      4 - Paysign, Inc. (0001496443) (Issuer)

      5/15/24 6:19:59 PM ET
      $PAYS
      Business Services
      Consumer Discretionary
    • Topline Capital Management, Llc bought $333,465 worth of shares (112,725 units at $2.96) (SEC Form 4)

      4 - Paysign, Inc. (0001496443) (Issuer)

      3/18/24 8:57:59 PM ET
      $PAYS
      Business Services
      Consumer Discretionary

    $PAYS
    Leadership Updates

    Live Leadership Updates

    See more
    • Paysign, Inc. Announces Acquisition of Gamma Innovation's Assets, Appoints Michael Ngo as Chief Innovation Officer

      Paysign Strengthens Leadership in Technology for Plasma and Pharmaceutical Industries  Paysign, Inc. (NASDAQ: PAYS), a leading provider of patient affordability solutions, financial technology products, and integrated payment processing services, today announced that it has acquired the assets of Gamma Innovation LLC (Gamma), significantly enhancing Paysign's capabilities in plasma donor and pharmaceutical patient engagement technologies. As part of this strategic acquisition, Paysign has appointed Michael Ngo, former Managing Member of Gamma, as its Chief Innovation Officer. "This acquisition represents an exciting milestone for Paysign as we accelerate our growth strategy and expand our

      3/25/25 8:05:00 AM ET
      $PAYS
      Business Services
      Consumer Discretionary

    $PAYS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Paysign Inc.

      SC 13G/A - Paysign, Inc. (0001496443) (Subject)

      11/14/24 7:00:30 AM ET
      $PAYS
      Business Services
      Consumer Discretionary
    • SEC Form SC 13G/A filed by Paysign Inc. (Amendment)

      SC 13G/A - Paysign, Inc. (0001496443) (Subject)

      2/12/24 12:36:58 PM ET
      $PAYS
      Business Services
      Consumer Discretionary
    • SEC Form SC 13G/A filed by Paysign Inc. (Amendment)

      SC 13G/A - Paysign, Inc. (0001496443) (Subject)

      1/24/24 4:05:27 PM ET
      $PAYS
      Business Services
      Consumer Discretionary

    $PAYS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Henry Daniel R exercised 20,000 shares at a strike of $4.45, increasing direct ownership by 20% to 119,800 units (SEC Form 4)

      4 - Paysign, Inc. (0001496443) (Issuer)

      6/2/25 9:00:10 PM ET
      $PAYS
      Business Services
      Consumer Discretionary
    • Director Newman Jeffrey B exercised 20,000 shares at a strike of $4.45, increasing direct ownership by 67% to 50,000 units (SEC Form 4)

      4 - Paysign, Inc. (0001496443) (Issuer)

      6/2/25 9:00:07 PM ET
      $PAYS
      Business Services
      Consumer Discretionary
    • CEO Newcomer Mark sold $758,927 worth of shares (168,307 units at $4.51), decreasing direct ownership by 2% to 8,768,579 units (SEC Form 4)

      4 - Paysign, Inc. (0001496443) (Issuer)

      6/2/25 9:00:09 PM ET
      $PAYS
      Business Services
      Consumer Discretionary

    $PAYS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Lake Street initiated coverage on PaySign with a new price target

      Lake Street initiated coverage of PaySign with a rating of Buy and set a new price target of $6.00

      12/20/24 8:45:02 AM ET
      $PAYS
      Business Services
      Consumer Discretionary
    • Barrington Research initiated coverage on PaySign with a new price target

      Barrington Research initiated coverage of PaySign with a rating of Mkt Perform and set a new price target of $4.00

      3/30/22 8:15:53 AM ET
      $PAYS
      Business Services
      Consumer Discretionary
    • PaySign downgraded by Ladenburg Thalmann

      Ladenburg Thalmann downgraded PaySign from Buy to Neutral

      3/24/22 7:30:30 AM ET
      $PAYS
      Business Services
      Consumer Discretionary

    $PAYS
    Financials

    Live finance-specific insights

    See more
    • Paysign, Inc. Reports First Quarter 2025 Financial Results

      First quarter 2025 total revenues of $18.60 million, up 41.0% from first quarter 2024 First quarter 2025 net income of $2.59 million, or diluted earnings per share of $0.05, versus net income of $309 thousand, or diluted earnings per share of $0.01, for first quarter 2024 First quarter 2025 Adjusted EBITDA of $4.96 million, up 193.3% from $1.69 million a year ago, while diluted Adjusted EBITDA per share was $0.09 versus $0.03 for first quarter 20241 Total plasma center count increased by four net centers during first quarter 2025, exiting the quarter with 484 centers; revenue per plasma center decreased to $6,517 compared to $7,414 for the same period last year; year-over-year plasma

      5/8/25 4:05:00 PM ET
      $PAYS
      Business Services
      Consumer Discretionary
    • Paysign, Inc. Reports Fourth Quarter and Full-Year 2024 Financial Results

      For the Full-Year Full-year 2024 total revenues of $58.38 million, up 23.5% from full-year 2023 Full-year 2024 net income of $3.82 million, or diluted earnings per share of $0.07, versus net income of $6.46 million, or diluted earnings per share of $0.12 for full-year 2023 Full-year 2024 Adjusted EBITDA of $9.62 million, up 43.3% from $6.71 million a year ago, while diluted Adjusted EBITDA per share was $0.17 versus $0.12 for full-year 20231 Total plasma center count increased by 16 during 2024, exiting the year with 480 centers, contributing to a 4.6% increase in plasma revenue versus the same period last year Added 33 net patient affordability programs during 2024, exiting the y

      3/25/25 4:03:00 PM ET
      $PAYS
      Business Services
      Consumer Discretionary
    • Paysign, Inc. Reports Second Quarter 2024 Financial Results

      Second quarter 2024 total revenues of $14.33 million, up 29.8% from second quarter 2023 Second quarter 2024 net income of $697 thousand, or diluted earnings per share of $0.01, versus net loss of $104 thousand, or diluted earnings per share of $(0.00) for second quarter 2023 Second quarter 2024 Adjusted EBITDA of $2.24 million, up 95.8% from $1.14 million for second quarter 2023, while diluted Adjusted EBITDA per share was $0.04 versus $0.02 for second quarter 20231 Total plasma center count increased by eight net new centers during second quarter 2024, exiting the quarter with 477 centers, contributing to a 12.6% increase in plasma revenue versus the same period last year Adde

      7/31/24 4:02:00 PM ET
      $PAYS
      Business Services
      Consumer Discretionary